Cancer Statistics, 2020
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020;70:7-30.
- Corresponding Author: Rebecca L.Siegel, MPH, Surveillance Research, American Cancer Society, 250 Williams St, NW, Atlanta, GA 30303-1002;(Rebecca.firstname.lastname@example.org).
Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths that will occur in the United States and compiles the most recent data on population-based cancer occurrence. Incidence data (through 2016) were collected by the Surveillance, Epidemiology, and End Results Program; the National Program of Cancer Registries; and the North American Association of Central Cancer Registries. Mortality data (through 2017) were collected by the National Center for Health Statistics.
美国癌症协会(American Cancer Society)每年都会对美国可能出现的新癌症病例和死亡人数进行估计，并汇编出基于人口的癌症发生的最新数据。发病率数据(截至2016年)由监察,流行病学调查及最终结果方案（SEER）;国家癌症登记计划;以及北美中央癌症登记协会收集。死亡率数据(截至2017年)由国家卫生统计中心收集。
In 2020, 1,806,590 new cancer cases and 606,520 cancer deaths are projected to occur in the United States. The cancer death rate rose until 1991, then fell continuously through 2017, resulting in an overall decline of 29% that translates into an estimated 2.9 million fewer cancer deaths than would have occurred if peak rates had persisted. This progress is driven by long-term declines in death rates for the 4 leading cancers (lung, colorectal, breast, prostate); however, over the past decade (2008-2017), reductions slowed for female breast and colorectal cancers, and halted for prostate cancer.
In contrast, declines accelerated for lung cancer, from 3% annually during 2008 through 2013 to 5% during 2013 through 2017 in men and from 2% to almost 4% in women, spurring the largest ever single-year drop in overall cancer mortality of 2.2% from 2016 to 2017. Yet lung cancer still caused more deaths in 2017 than breast, prostate, colorectal, and brain cancers combined.
Recent mortality declines were also dramatic for melanoma of the skin in the wake of US Food and Drug Administration approval of new therapies for metastatic disease, escalating to 7% annually during 2013 through 2017 from 1% during 2006 through 2010 in men and women aged 50 to 64 years and from 2% to 3% in those aged 20 to 49 years; annual declines of 5% to 6% in individuals aged 65 years and older are particularly striking because rates in this age group were increasing prior to 2013. It is also notable that long-term rapid increases in liver cancer mortality have attenuated in women and stabilized in men.
在美国食品和药物管理局批准转移性疾病新疗法之后，近期皮肤黑素瘤的死亡率也急剧下降, 在2013-2017年间，黑色素瘤死亡率每年下降达到7%。而之前的2006-2010年间，50至64岁的黑色素瘤患者死亡率每年下降仅1%，在20至49岁的人群中为 2%到3%。年龄在65岁及以上的人每年减少情况尤为明显下降率达5%至6%，因为这个年龄段的死亡率在2013年之前一直在上升。同样值得注意的是，肝癌死亡率的长期快速增长在女性中逐渐减弱，在男性中保持稳定。
In summary, slowing momentum for some cancers amenable to early detection is juxtaposed with notable gains for other common cancers.